Pellis Care is addressing a $100bn global unmet clinical need in chronic wounds that affect around 100 million people worldwide. The product, PCDFU23, is a novel topical formulation, of an immuno-modulatory molecule with a well-established safety profile, that has shown early signs of efficacy in the treatment of chronic wounds. The Pellis Care management team has extensive experience in research and development, and the regulatory process for pharmaceutical products. Our unique combination of skills and experience is ideal to create potential new therapies and new intellectual property.